Akero Therapeutics Inc’s recently made public that its Officer PATRICK D LAMY acquired Company’s shares for reported $0.29 million on Apr 07 ’25. In the deal valued at $36.73 per share,8,000 shares were bought.
Then, Graham G. Walmsley bought 91,309 shares, generating $4,085,804 in total proceeds. Upon buying the shares at $44.75, the Director now owns 1,091,309 shares.
Before that, Graham G. Walmsley bought 58,691 shares. Akero Therapeutics Inc shares valued at $2,524,417 were divested by the Director at a price of $43.01 per share. As a result of the transaction, Graham G. Walmsley now holds 1,150,000 shares, worth roughly $41.37 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -2.07% to $35.97. Over the last five days, the stock has lost -11.14%. Akero Therapeutics Inc shares have risen nearly 29.30% since the year began. Nevertheless, the stocks have risen 56.60% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $47.12, while 200 days put it at $32.53.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 33.77, which if violated will result in even more drops to 31.56. On the upside, there is a resistance level at 38.50. A further resistance level may holdings at 41.02. The Relative Strength Index (RSI) on the 14-day chart is 32.61, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.40%. Stochastics %K at 13.27% indicates the stock is a buying.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-03-14, growing by 0.42 million shares to a total of 5.2 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.79 million shares. There was a rise of 8.03%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
